Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$4.02 USD
-0.12 (-2.90%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.04 +0.02 (0.50%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Arbutus Biopharma Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -72.85 | -69.46 | -76.25 | -63.75 | -153.72 |
Depreciation/Amortization & Depletion | 1.40 | 1.43 | 1.75 | 1.98 | 68.34 |
Net Change from Assets/Liabilities | -18.23 | 29.24 | 0.93 | 0.43 | -2.23 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.74 | 3.43 | 6.03 | 9.90 | 16.61 |
Net Cash From Operating Activities | -85.94 | -35.36 | -67.53 | -51.44 | -71.01 |
Property & Equipment | -0.99 | -0.51 | -0.81 | -0.23 | -0.58 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 51.76 | -74.43 | -11.87 | -14.68 | 28.92 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 50.77 | -74.94 | -12.68 | -14.91 | 28.34 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 30.65 | 31.81 | 137.24 | 86.75 | 18.91 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 18.55 |
Net Cash from Financing Activities | 30.65 | 31.81 | 137.24 | 86.75 | 37.46 |
Effect of Exchange Rate Changes | 0.03 | -0.02 | 0.01 | 0.06 | 0.07 |
Net Change In Cash & Equivalents | -4.49 | -78.51 | 57.03 | 20.45 | -5.14 |
Cash at Beginning of Period | 30.78 | 109.28 | 52.25 | 31.80 | 36.94 |
Cash at End of Period | 26.29 | 30.78 | 109.28 | 52.25 | 31.80 |
Diluted Net EPS | -0.44 | -0.46 | -0.83 | -1.00 | -2.89 |
Fiscal Year End for Arbutus Biopharma Corporation falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -37.67 | -17.88 | -72.85 | -53.54 | -33.43 |
Depreciation/Amortization & Depletion | 0.71 | 0.36 | 1.40 | 1.05 | 0.68 |
Net Change from Assets/Liabilities | -0.10 | -2.86 | -18.23 | -19.72 | -16.34 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.26 | 1.08 | 3.74 | 3.57 | 2.24 |
Net Cash From Operating Activities | -33.80 | -19.30 | -85.94 | -68.64 | -46.86 |
Property & Equipment | -0.10 | -0.10 | -0.99 | -0.99 | -0.98 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 21.62 | 11.79 | 51.76 | 29.54 | 19.10 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 21.52 | 11.69 | 50.77 | 28.55 | 18.12 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 48.80 | 24.43 | 30.65 | 26.84 | 25.16 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 48.80 | 24.43 | 30.65 | 26.84 | 25.16 |
Effect of Exchange Rate Changes | -0.02 | -0.01 | 0.03 | 0.01 | 0.00 |
Net Change In Cash & Equivalents | 36.50 | 16.82 | -4.49 | -13.25 | -3.58 |
Cash at Beginning of Period | 26.29 | 26.29 | 30.78 | 30.78 | 30.78 |
Cash at End of Period | 62.79 | 43.10 | 26.29 | 17.53 | 27.20 |
Diluted Net EPS | -0.11 | -0.10 | -0.12 | -0.12 | -0.10 |